Login to Your Account



Cardiorentis' Heart Failure Trial Backed by $131M Investment

By Nuala Moran
Staff Writer

Wednesday, December 5, 2012

The secretive backers of Cardiorentis Ltd. prefer to remain anonymous, but they obviously are expecting to see the name of the company's main asset, Ularitide, in lights, having made a €100 million (US$130.6 million) investment to put the product through a Phase III trial in treating 2,116 patients with acute heart failure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription